KPIs & Operating Metrics(New)

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Aquestive Therapeutics (AQST) Long-Term Debt Repayments (2019 - 2026)

Aquestive Therapeutics has reported Long-Term Debt Repayments over the past 3 years, most recently at $9.1 million for Q1 2023.

For Q1 2023, Long-Term Debt Repayments changed N/A year-over-year to $9.1 million; the TTM value through Mar 2023 reached $31.6 million, up 40.38%, while the annual FY2025 figure was $26000.0, 13.04% up from the prior year.
Long-Term Debt Repayments for Q1 2023 was $9.1 million at Aquestive Therapeutics, down from $22.5 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $49.4 million in Q3 2019 and troughed at $9.1 million in Q1 2023.
A 3-year average of $27.0 million and a median of $22.5 million in 2020 define the central range for Long-Term Debt Repayments.